Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
32571-1-PBS targets EPS8L3 in WB, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag38525 Product name: Recombinant human EPS8L3 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 408-593 aa of NM_001319952.1 Sequence: PVSLRRGSHRLGSTSHFPQEKTHNHDPQPGDPNSRPSSPKPAQPALKMQVLYEFEARNPRELTVVQGEKLEVLDHSKRWWLVKNEAGRSGYIPSNILEPLQPGTPGTQGQSPSRVPMLRLSSRPEEVTDWLQAENFSTATVRTLGSLTGSQLLRIRPGELQMLCPQEAPRILSRLEAVRRMLGISP* 相同性解析による交差性が予測される生物種 |
| Full Name | EPS8-like 3 |
| Calculated molecular weight | 67kDa，593aa |
| Observed molecular weight | 65 kDa |
| GenBank accession number | NM_001319952.1 |
| Gene Symbol | EPS8L3 |
| Gene ID (NCBI) | 79574 |
| RRID | AB_3742659 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity Purification |
| UNIPROT ID | Q8TE67 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
EPS8L3 (epidermal growth factor receptor kinase substrate 8-like protein 3) is a member of the EPS8 family, encoding a protein associated with the epidermal growth factor receptor (EGFR) signaling pathway. Studies have shown that EPS8L3 is highly expressed in a variety of tumors, such as hepatocellular carcinoma (HCC), pancreatic cancer, and gastric cancer, and is closely associated with tumor proliferation, migration, and invasive ability. It promotes tumor cell proliferation and inhibits apoptosis by activating GSK3β and PI3K/AKT/mTOR signaling pathways. In addition, high expression of EPS8L3 is associated with poor prognosis in tumor patients and may serve as a biomarker for tumor diagnosis and prognostic assessment. Due to its important role in tumors, EPS8L3 is considered a potential therapeutic target, and its inhibition may enhance the efficacy of multi-target kinase inhibitors.